# US 2001/0025043 A1 · New pharmaceutical active compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025043 A1
- Document ID: US20010025043A1
- Status: Published application
- Kind: A1
- Application number: 09/865,231
- Filed: 2001-05-25
- Published: 2001-09-27
- Earliest claimed: 1996-09-25
- Assignees: Astra Aktiebolag, a Sweden corporation
- Inventors: Hakan Bergstrand; Kostas Karabelas; Peter Sjo
- Web page: https://patentgrep.com/patent/US20010025043A1

## CPC

- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 475/00: Heterocyclic compounds containing pteridine ring systems
- C07D 475/02: with an oxygen atom directly attached in position 4
- C07H 19/04: Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention provides optionally substituted and/or annulated compounds of formula (I) 1 wherein X, Y, Z and A is each independently carbon or nitrogen, and at least two of X, Y, Z and A are carbon; and pharmaceutically acceptable salts thereof with the proviso that: 3-(1H-Indol-3-yl)-1H-quinoxalin-2-one, 3-(2-Methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and 3-(1,2-Diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one are excluded from compounds of formula (I). The invention includes the use of compounds of formula (I) in medical therapy, particularly in the therapy of conditions requiring inhibition of protein kinase C.

## Claims

### Claim 1

An optionally substituted and/or annulated compound of formula (I): 7
wherein X, Y, Z and A is each independently carbon or nitrogen, and at least two of X, Y, Z and A are carbon;
and pharmaceutically acceptable salts thereof,
with the proviso that:
3-(1H-Indol-3-yl)-1H-quinoxalin-2-one,
3-(2-Methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and
3-(1,2-Diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one
are excluded from compounds of formula (I).

### Claim 2 (depends on 1)

A compound according to claim 1, of formula (IA): 8
wherein X, Y, Z and A are as defined in claim 1,
R1, R2, R3, and R4 is each independently H, hydroxy, amino, nitro, halo, C1-6 alkyl, phenylC1-6 alkyl, C1-6 alkoxy, haloC1-6 alkyl, carboxyC1-6 alkyl ester or R1 and R2 or R2 and R3 or R3 and R4 form an annulated aromatic ring, or when the atom to which it would be attached is nitrogen, is absent;
R5 and R6 is each independently H, C1-6 alkyl, hydroxyC1-6 alkyl, aminoC1-6 alkyl, phenylC1-6 alkyl, carboxyC1-6 alkyl, C1-6 alkenyl, (phenylC1-3 alkoxy)C1-3 alkyl, (C1-6 acyloxy)C1-6 alkyl, (C1-6 alkoxycarbonyl)C1-6 alkyl, (mono- or di-C1-6 alkyl)aminoC1-6 alkyl, (C1-6 alkyl)aminocarbonylC1-6 alkyl, (C1-6 acylamino)C1-6 alkyl, (aminoC1-3 alkylphenyl)C1-3 alkyl, or aminodeoxysugar;
R7 and R8 is each independently H, amino, nitro, hydroxy, halogen,
C1-6 alkoxy, phenylC1-6 alkoxy or carboxyC1-6 alkyl ester;
R9 is H, C1-6 alkyl, phenyl, halophenyl or phenylC1-6 alkyl and wherein when R5 and R9 together comprise3-5 carbons they may be linked to generate a cyclic moiety which may be aminoC1-6 alkyl substituted;
and wherein at least one of R1 to R9 is not H and wherein when the only one of R1 to R9 which is not H is R9, R9 is not methyl;
and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

A compound according to claim 2, wherein at least one of R5 and R6 is aminoC1-6alkyl.

### Claim 4 (depends on 1, 2, 3)

A compound according to any of claims 1 to 3, wherein at least one of Y and Z is substituted.

### Claim 5 (depends on 1, 2, 3, 4)

A compound according to any one of claims 1 to 4, wherein at least one of Y and Z is substituted with halo, methoxy or carboxylic ester.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A compound according to any one of claims 1 to 5 wherein position 5 of the indole is substituted.

### Claim 7 (depends on 2, 3, 4, 5, 6)

A compound according to any one of claims 2 to 6 wherein R9 is H or alkyl.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

A compound according to any one of claims 2 to 7 wherein R5 or R6 is an aminodeoxysugar, comprising a six membered ring.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7)

A compound according to any one of claims 2 to 7 wherein R5 and R9 together form a six membered ring.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A compound according to any one of claims 1 to 9 wherein three or four of X,Y,Z and A are carbon.

### Claim 11 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound according to any one of claims 2 to 10 wherein R1 and R2, or R2 and R3, or R3 and R4 form an annulated aromatic ring.

### Claim 12

The compounds:
3-[3-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]propyl-ammonium acetate,
3-[3-(6,7-Dichloro-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
3-[3-(6,7-Dichloro-3-oxo-3,4-dihydro-quinoxalin-2-yl)-5-methoxycarbonyl-indol-1-yl]-propyl-ammonium acetate,
3-[3-(6,7-Dichloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-5-methoxycarbonyl-indol-1-yl]-propyl-ammonium acetate,
3-[5-Methoxycarbonyl-3-(7-methoxy-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
3-[3-(4-tert-Butoxycarbonylmethyl-7-methoxy-3-oxo-3,4-dihydro-quinoxalin-2-yl)-5-methoxycarbonyl-indol-1-yl]propyl-ammonium acetate,
3-[3-(4-(3-Ammoniumpropyl)-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]propyl-ammonium bis trifluoroacetate,
Dimethyl-{3-[3-(1-methyl-1H-indol-3-yl)-2-oxo-2H-quinoxalin-1-yl]-propyl}-ammonium trifluoroacetate,
3-[3-(3-Oxo-3,4-dihydro-benzo[g]quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
3-[6-Benzyloxy-3-(7-methoxy-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
3-[5-Benzyloxy-3-(4-tert-butoxycarbonylmethyl-7-methoxy-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
3-[2-(4-Chloro-phenyl)-3-(7-methoxy-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
3-[2-(4-Chloro-phenyl)-3-(7-methoxy-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
3-[3-(6,7-Dichloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-2-ethyl-indol-1-yl]-propyl-ammonium acetate,
3-[3-(5-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-6-nitro-indol-1-yl]-propyl-ammonium acetate,
3-[6-Nitro-3-(6-nitro-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
4-[3-(3-Oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-ylmethyl]benzyl-ammonium acetate,
3-[3-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-ylmethyl]benzyl-ammonium trifluoroacetate,
3-[3-(4-Benzyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium trifluoroacetate;
and other pharmaceutically acceptable salts thereof.

### Claim 13

The compound:
3-[3-(3-Oxo-3,4-dihydro-benzo[g]quinoxalin-2-yl)-indol-1-yl]-propyl-ammonium acetate,
and other pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 12)

A free amine of a compound according to claim 12.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A compound according to any one of claims 1 to 13, for use in medical therapy.

### Claim 16 (depends on 15)

A compound according to claim 15 wherein the medical therapy is the treatment of inflammatory, immunological, bronchopulmonary, cardiovascular, oncological or CNS-degenerative disorders.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

Use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament for use in the treatment of inflammatory, immunological, bronchopulmonary, cardiovascular, oncological or CNS-degenerative disorders.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method for the treatment of an inflammatory, immunological, bronchopulmonary, cardiovascular, oncological or CNS-degenerative disorder, wherein a therapeutically effective amount of a compound according to any one of claims 1 to 13 is administered to a mammal in the need of such treatment.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition wherein the active ingredient is a compound according to any one of claims 1 to 13.

### Claim 20 (depends on 1, 2)

A compound of formula (II): 9
wherein X, Y, Z, A, are as defined in claim 1; R1 to R9 are as defined in claim 2 and at least one of R5 and R6 carries a protected amino, carboxy or hydroxy group, or
a compound of formula (III) 10
wherein R5, R7, R8, and R9 are as defined in claim 2, but when R5 carries an amino, carboxy or hydroxy groups, such group is in a protected form; and LG is a leaving group.

### Claim 21 (depends on 1, 2)

A process for the preparation of a compound according to claim 2 when at least one of R5 and R6 of formula (IA) carries an amino, carboxy or hydroxy group, and pharmaceutically acceptable salts thereof, comprising:
a) deprotecting a compound of formula (II) corresponding to formula (IA) but in which at least one of R5 and R6 carries protected amino, carboxy or hydroxy groups, or
b) converting a compound of formula (IA), in which at least one of R5 and R6 carries amino or carboxy groups
i) to a pharmaceutically acceptable salt thereof, or vice versa; or
ii) a pharmaceutically acceptable salt of a compound of formula (IA) into a different pharmaceutically acceptable salt; or
when R6 is hydrogen, comprising reacting a compound of formula (III): 11
wherein R5, R7, R8, and R9 are as defined in claim 2 and LG is a leaving group, with a compound of formula (IV): 12
wherein R1-R4 are as defined in claim 2 and A, X, Y, and Z are as defined in claim 1; and when R5 in formula (III) carries an amino, carboxy or hydroxy groups such groups are suitably protected and the protecting group removed in a subsequent deprotecting step; or
when R6 is other than H, comprising reacting a compound of formula (II) which corresponds to formula (I), but in which R6 is H, with a suitable alkylating agent in the presence of a base and wherein when R5 in formula (II) or the alkylating agent carries an amino, carboxy or hydroxy group, such group is suitably protected and the protecting group removed in a subsequent deprotecting step.
